Mochida Pharmaceutical Co., Ltd. (FRA:MFY)

Germany · Delayed Price · Currency is EUR

17.50

+0.50 (2.94%)

Last updated: Oct 13, 2026, 8:24 AM CET

Market Cap	627.70M +2.1%
Revenue (ttm)	657.18M +14.7%
Net Income	49.47M +52.5%
EPS	1.40 +52.5%
Shares Out	n/a
PE Ratio	12.69
Forward PE	n/a
Dividend	0.45 (2.60%)
Ex-Dividend Date	Sep 29, 2026

Volume	2
Open	17.50
Previous Close	17.00
Day's Range	17.50 - 17.50
52-Week Range	16.20 - 21.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatologists, psychiatry, and gastroenterological, including Realda and Collagen for the treatment of ulcerative colitis; Goofis and Movicol for the treatment of chronic constipation; interstitial pulmonary hypertension for the treatment of pulmonary arterial hypertension; Treprospermid, for pulmonary hypertension associated with ulcer... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1913

Employees 1,479

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol MFY

Financial Performance

In fiscal year 2026, Mochida Pharmaceutical's revenue was 116.95 billion, an increase of 11.21% compared to the previous year's 105.16 billion. Earnings were 7.90 billion, an increase of 39.01%.

Financial numbers in JPY Financial Statements